Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. - Wikidata - awgldk - TriplyDB

Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.

Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.

http://www.wikidata.org/entity/Q37635032

about

HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment Evolving clinical phenotypes in HIV-associated neurocognitive disorders The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment.Clinical Trials in Neurovirology: Successes, Challenges, and Pitfalls Rates of non-confounded HIV-associated neurocognitive disorders in men initiating combination antiretroviral therapy during primary infection.Neurocognitive development in HIV-positive children is correlated with plasma viral loads in early childhood The impact of covariate misclassification using generalized linear regression under covariate-adaptive randomization.Host genetic factors predisposing to HIV-associated neurocognitive disorder.Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders Anti-tat Hutat2:Fc mediated protection against tat-induced neurotoxicity and HIV-1 replication in human monocyte-derived macrophages Controversies in HIV-associated neurocognitive disorders Early viral suppression improves neurocognitive outcomes in HIV-infected children.Cerebrospinal fluid (CSF) CD8+ T-cells that express interferon-gamma contribute to HIV associated neurocognitive disorders (HAND)Envelope gene evolution and HIV-1 neuropathogenesis.Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment.Update on HIV dementia and HIV-associated neurocognitive disorders.Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.HIV-associated Neurocognitive Disorders and Antiretroviral Therapy: Current Concepts and Controversies.CNS reservoirs for HIV: implications for eradication.CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.Interventions for Neurocognitive Dysfunction.Neurologic Complications in Treated HIV-1 Infection.Update and New Directions in Therapeutics for Neurological Complications of HIV Infections.Treating HIV Infection in the Central Nervous System.Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication.Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations.Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics.Editorial commentary: protease inhibitor monotherapy: safe for the CNS in durably suppressed patients?Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.No Neurocognitive Advantage for Immediate Antiretroviral Treatment in adults with greater than 500 CD4+ T Cell Counts.Neurological Complications of HIV Infection.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015

P2860

Q26766448-A40B51FB-5824-4963-9834-EF8079E10366 Q26859192-20F09A8A-3503-4BEE-BE25-31C4837CEFB1 Q28066725-09285D45-9CC9-4B4E-A573-C14C5B0F476E Q30234305-AC289E97-C703-4EB4-828D-19DAB3911E21 Q30250271-D01F741F-D64C-4D95-8269-B7F13EC3A439 Q30690955-71642078-F59C-4AC5-AAE4-BEFB8867CF64 Q33783344-E1D88853-53DC-479A-A5EE-3F61748FB2EA Q33812362-F801D115-B58F-406F-A4B0-F95F4DF65858 Q34001122-DD1F18B4-0E11-4038-AF01-D3EEECB67A56 Q34507098-C8D8BA7E-E3AD-481F-AE38-06E9343237F2 Q34632979-ADB28DE1-8469-4A96-892C-3478052FF180 Q35037015-4EDA9A23-42CE-408E-983B-CE12AAE8A6E8 Q35095168-6AD8B51A-69EF-47BC-8AA0-9D917761008E Q35125862-0F80EBB4-2718-43C4-AA4C-EDC92EAEB12C Q36847475-98AB05C4-99B8-4097-9F26-BF07E6A2C94D Q37098390-BE7B3C6E-AA55-4B56-A572-3084EEBF19FC Q37720509-351F5667-0BDB-48BB-AD42-791D035A8F80 Q38220991-25BB2EA3-611C-411C-B7A6-BD5E8FD3A862 Q38247035-655B997F-41BC-4055-8A1E-1FAA5C6E1FF4 Q38444808-EEAE1378-BE17-4C11-A524-2BE1C4BFE05F Q38597765-264C1CE6-CCE2-4857-9DC8-E9DB7617F0E3 Q38702121-E3E591E6-0D60-4B4B-B95D-392CA0A9E8BE Q38767396-297395A5-0693-4A3C-80B5-DAC46E45C98E Q38832560-DA1E871E-7EC9-4617-8369-6F7A296E6FAB Q38887659-BF854556-4A55-4E9A-853D-E36F9E9C7AAE Q39077816-ABCC97E8-57B8-4124-8A4B-DE37D413205D Q39525851-3465C470-5B2C-4369-8422-46F5F2255655 Q40215533-C35383FB-D3E8-4801-9434-CF7557ACDD3A Q40463006-4BE3EC9C-0C6D-4543-B8D3-76C67E9DEA35 Q40478740-C5D6F2E0-E7F9-48D9-9E39-F01EA7801514 Q41208022-A0707850-6C28-4AB3-99DF-698057DA0FAE Q42203691-6B054189-716E-4923-A5B4-0BE017D60D01 Q43166791-FC9CF684-EA52-4F24-85ED-5DDFDEA13164 Q49711913-63F187FB-8E35-4D70-A31A-F36D6EDF95AD Q50051625-5E4E2C4C-9042-44C8-8D15-D67A88B24032 Q52774286-3397E64F-69FE-44A3-A29C-60731E7E01F9 Q57180790-8B054FE1-227B-470E-B157-7E18D09320AA

P2860

Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder.

http://www.wikidata.org/entity/Q37635032

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 December 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Randomized trial of central ne ...... iated neurocognitive disorder.

@en

Randomized trial of central ne ...... iated neurocognitive disorder.

@nl

type

label

Randomized trial of central ne ...... iated neurocognitive disorder.

@en

Randomized trial of central ne ...... iated neurocognitive disorder.

@nl

prefLabel

Randomized trial of central ne ...... iated neurocognitive disorder.

@en

Randomized trial of central ne ...... iated neurocognitive disorder.

@nl

P1433

Q37635032-2E5578A3-37BA-4DFA-906C-3E4ADD719BD4

P1476

Q37635032-0F360654-F546-4500-A04A-2291FB6B3011

P2093

Q37635032-0B0E04F8-5407-4563-85D8-F3C1BF4948F8

Q37635032-2113F3B6-887D-44FA-9287-F5897C9A92B5

Q37635032-2360F61C-3068-45E8-8ABD-8209ECB96656

Q37635032-28102C36-2DE7-4B25-8A5F-F6279F8F4630

Q37635032-32299109-0D50-42DB-8E19-AE8BA7F66158

Q37635032-4FFC965D-851B-4B2D-A18F-3B2A94327360

Q37635032-5B5FE09C-1826-4FE3-9024-A3764951D8E1

Q37635032-5C31769E-6A27-4B2C-A275-825CD6DF3453

Q37635032-68657413-3C01-408C-A261-1E0EF77E5B48

Q37635032-72BCDA96-8E34-4109-A6BA-E6BA05B5B966

P2860

Q37635032-046788AC-7DB5-4ECE-A7F7-6562B24392AB

Q37635032-112D543F-F819-4C9D-87FC-C5C44A0ED117

Q37635032-28D8C09C-96E1-4308-9713-1C7F7A83AFEA

Q37635032-3409C387-9271-4B03-B947-92D54AFC7A5F

Q37635032-6204771B-7E68-4FC5-8E2C-7DEDA75FD351

Q37635032-6C70955E-61A4-4DE4-AFDA-6FB3469D6879

Q37635032-8A83768B-2E48-41D9-980A-2B86E1119019

Q37635032-91AD896F-AF64-4A02-B5B8-F301E655188F

Q37635032-A10BA59B-ACE6-43DE-B3EE-FA3E4687ED09

Q37635032-A3AD6310-AF73-4E96-900B-2D611D42C3F2

P304

Q37635032-9422F21A-3478-4D9A-A35B-D602CDF984E3

P31

Q37635032-A5AF19BA-553E-46E2-9C13-6764A8C3DF3F

P356

Q37635032-50C8A2E0-75E8-46AB-875D-D764BA2F5331

P407

Q37635032-8657D7E3-95B2-4482-A433-EF0394175DCA

P433

Q37635032-E898E6A6-B9CB-4D3D-843A-CC10BB49AD51

P478

Q37635032-12B3C8A0-562B-4FC1-B02C-7F7F31F7FCA8

P50

Q37635032-6AFB29FF-137A-42C5-A53E-A2BC850A53D3

Q37635032-F7DB4473-64B3-47D7-B668-13A16522445B

Q37635032-FAC2ED0E-4C3A-4385-A09C-19C8F94A2078

P577

Q37635032-D5D98086-63EF-44C1-B06D-080CFC0B9B86

P5875

Q37635032-F9DA5D22-B21F-4F6B-982D-8B42EE3D49AE

P698

Q37635032-2343E606-4450-4156-8497-81332D7CA39B

P921

Q37635032-350A2208-9667-4210-9487-EC4321084B85

Q37635032-FDF5B4AC-1070-4556-87B7-9E7CD5D67118

P932

Q37635032-67099F2F-0187-4E9B-B284-AE2377A59C35

P356

P1433

Clinical Infectious Diseases

P1476

Randomized trial of central ne ...... iated neurocognitive disorder.

@en

P2093

Anya Umlauf

http://www.w3.org/2001/XMLSchema#string

Brookie M Best

http://www.w3.org/2001/XMLSchema#string

Chelsea Sanders

http://www.w3.org/2001/XMLSchema#string

Cheryl Jay

http://www.w3.org/2001/XMLSchema#string

Craig Ballard

http://www.w3.org/2001/XMLSchema#string

David B Clifford

http://www.w3.org/2001/XMLSchema#string

David M Simpson

http://www.w3.org/2001/XMLSchema#string

Florin Vaida

http://www.w3.org/2001/XMLSchema#string

J Allen McCutchan

http://www.w3.org/2001/XMLSchema#string

Mariana Cherner

http://www.w3.org/2001/XMLSchema#string

P2860

A multiple testing procedure for clinical trials

Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change.

Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research.

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

Updated research nosology for HIV-associated neurocognitive disorders

Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz.

Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance.

Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy

Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system

Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.

P304

1015-1022

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIT921

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Robert K Heaton

P577

2013-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259387067

http://www.w3.org/2001/XMLSchema#string

P698

24352352

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

P932

3952601

http://www.w3.org/2001/XMLSchema#string